IP Library Granted Patent US 9,802,933
Granted Patent B2
US 9,802,933 · App. 15/380,239 · Granted Oct 31, 2017

Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives

Inventors: Ben C. Askew (Marshfield, MA); Richard W. Heidebrecht (Somerville, MA); Takeru Furuya (Cambridge, MA); Mark E. Duggan (Wellesley, MA)
Assignee: SciFluor Life Sciences, Inc.
C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,802,933
App. No.
15/380,239
Granted
Oct 31, 2017
Kind
B2
Abstract

The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described.

Claims (31)

1. A method of treating a condition mediated by increased bone resorption in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I:

or a pharmaceutically acceptable salt or solvate thereof, wherein

X is selected from CH and N;

Y is selected from CH and N;

R 1 is C 1 -C 6 alkoxy wherein said C 1 -C 6 alkoxy is substituted with 0, 1, 2, 3, 4, or 5 fluorine atoms; and

R 2 and R 3 are each independently selected from H and F,

or R 2 and R 3 taken together with the carbon atom to which they are attached form a 3- or 4-membered carbocyclic or heterocyclic ring,

provided that the compound of formula I contains at least one fluorine atom.

2. The method of claim 1 , wherein the compound of formula I is of formula II:

3. The method of claim 1 , wherein the compound of formula I is of formula III:

4. The method of claim 1 , wherein the compound of formula I is of formula IV:

5. The method of claim 1 , wherein the compound of formula I is of formula V:

6. The method of claim 1 , wherein the compound of formula I is selected from

7. The method of claim 1 , wherein the condition is selected from osteopenia due to bone metastases, periarticular erosions in rheumatoid arthritis, Paget's disease, and immobilization-induced osteopenia.

8. The method of claim 1 , wherein the condition is osteoporosis induced by estrogen deficiency, immobilization, or glucocorticoid.

9. The method of claim 1 , wherein the condition is senile osteoporosis.

10. The method of claim 1 , wherein the condition is malignant hypercalcemia.

11. A method of alleviating pain associated with an osteolytic lesion in a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I:

or a pharmaceutically acceptable salt or solvate thereof, wherein

X is selected from CH and N;

Y is selected from CH and N;

R 1 is C 1 -C 6 alkoxy wherein said C 1 -C 6 alkoxy is substituted with 0, 1, 2, 3, 4, or 5 fluorine atoms; and

R 2 and R 3 are each independently selected from H and F,

or R 2 and R 3 taken together with the carbon atom to which they are attached form a 3- or 4-membered carbocyclic or heterocyclic ring,

provided that the compound of formula I contains at least one fluorine atom.

12. The method of claim 11 , wherein the compound of formula I is of formula II:

13. The method of claim 11 , wherein the compound of formula I is of formula III:

14. The method of claim 11 , wherein the compound of formula I is of formula IV:

15. The method of claim 11 , wherein the compound of formula I is of formula V:

16. The method of claim 11 , wherein the compound of formula I is selected from

17. The method of claim 11 , wherein the disease is osteoporosis, osteodystrophy, Paget's disease, myositis ossificans, Bechterew's disease, malignant hypercalcemia, metastatic bone disease, periodontal disease, cholelithiasis, nephrolithiasis, urolithiasis, urinary calculus, sclerosis, arthritis, bursitis, neuritis, or tetany.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2026
From: OCUTERRA THERAPEUTICS, INC. (FORMERLY KNOWN AS SCIFLUOR LIFE SCIENCES, INC.)
To: FELIQS CORPORATION
Reel/Frame 073443/0692 →
CHANGE OF NAME Recorded Nov 3, 2022
From: SCIFLUOR LIFE SCIENCES, INC.
To: OCUTERRA THERAPEUTICS, INC.
Reel/Frame 061871/0762 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2016
From: SCIFLUOR LIFE SCIENCES, LLC
To: SCIFLUOR LIFE SCIENCES, INC.
Reel/Frame 040693/0200 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2016
From: ASKEW, BEN C.; HEIDEBRECHT, RICHARD W.; FURUYA, TAKERU; DUGGAN, MARK E.
To: SCIFLUOR LIFE SCIENCES, LLC
Reel/Frame 040669/0639 →
Continuity (5)
Continuation 15000311 · Jan 19, 2016
Continuation 14533819 · Nov 5, 2014
Continuation 14175501 · Feb 7, 2014
Provisional Application 61762087 · Feb 7, 2013
Related Publication 20170096427A1 · Apr 6, 2017